ArticleJournal of the American Heart Association2026
Beyond Hemoglobin Levels: Integrating Anemia Phenotyping Into Prognostic Models for Patients With Stroke Following Intravenous Thrombolysis.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnemia predicts poor outcomes after intravenous thrombolysis in acute ischemic stroke. Whether morphological anemia subtypes differentially affect prognosis remains unclear. We evaluated the impact of microcytic, normocytic, and macrocytic anemia on outcomes in patients with acute ischemic stroke receiving intravenous thrombolysis.
methodsIn this multicenter, prospective cohort study of 1367 patients with acute ischemic stroke treated with intravenous thrombolysis, anemia was defined using World Health Organization criteria and classified by mean corpuscular volume. Multivariable logistic regression and mediation analyses were performed.
resultsAmong 1367 patients (median age 66 years, 64.7% male), 379 (27.7%) had anemia: 123 (8.9%) microcytic, 202 (14.7%) normocytic, and 54 (3.9%) macrocytic. After full adjustment, microcytic and normocytic anemia were independently associated with increased risks of 3-month death or severe disability (microcytic: adjusted odds ratio [aOR], 2.13 [95% CI, 1.34-3.38]; normocytic: aOR, 2.07 [95% CI, 1.39-3.09]) and 3-month mortality (microcytic: aOR, 1.76 [95% CI, 1.05-2.96]; normocytic: aOR, 1.88 [95% CI, 1.21-2.91]). Normocytic anemia was additionally associated with in-hospital neurological deterioration (aOR, 1.83 [95% CI, 1.10-3.04]), stroke-associated pneumonia (aOR, 2.35 [95% CI, 1.57-3.51]), and in-hospital gastrointestinal bleeding (aOR, 2.58 [95% CI, 1.18-5.64]). Stroke-associated pneumonia mediated 22.09%, 45.91% and 27.05% of the effect of normocytic anemia on 3-month death or severe disability, 3-month mortality, and in-hospital neurological deterioration, respectively. Macrocytic anemia showed no significant associations with outcomes.
conclusionsMorphological anemia subtypes have distinct prognostic implications in intravenous thrombolysis-treated patients with acute ischemic stroke. Microcytic and normocytic anemia are independently associated with poor outcomes and mortality, with in-hospital complications, particularly stroke-associated pneumonia, mediating substantial risk. REGISTRATION: URL: https://www.chictr.org.cn/; Unique Identifier: ChiCTR2000033456.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.